Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $22.20

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned a consensus recommendation of “Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $22.20.

LXEO has been the subject of several recent analyst reports. Chardan Capital dropped their target price on shares of Lexeo Therapeutics from $25.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, April 8th. Leerink Partners cut their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th. Royal Bank of Canada decreased their target price on Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 25th. Finally, HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, April 8th.

Institutional Investors Weigh In On Lexeo Therapeutics

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in Lexeo Therapeutics by 86.5% during the 3rd quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after buying an additional 256,635 shares in the last quarter. State Street Corp increased its position in Lexeo Therapeutics by 29.4% in the third quarter. State Street Corp now owns 253,946 shares of the company’s stock worth $2,296,000 after purchasing an additional 57,674 shares during the last quarter. Barclays PLC raised its stake in Lexeo Therapeutics by 162.2% during the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock valued at $454,000 after purchasing an additional 31,057 shares in the last quarter. Wellington Management Group LLP lifted its position in Lexeo Therapeutics by 48.3% during the fourth quarter. Wellington Management Group LLP now owns 76,981 shares of the company’s stock valued at $507,000 after purchasing an additional 25,089 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in shares of Lexeo Therapeutics by 19.6% in the 4th quarter. Rhumbline Advisers now owns 25,197 shares of the company’s stock worth $166,000 after buying an additional 4,127 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

Lexeo Therapeutics Stock Down 1.5 %

NASDAQ LXEO opened at $4.64 on Friday. Lexeo Therapeutics has a 52 week low of $1.45 and a 52 week high of $19.50. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $154.03 million, a P/E ratio of -1.47 and a beta of 1.27. The stock’s 50-day moving average price is $3.01 and its 200-day moving average price is $5.41.

Lexeo Therapeutics (NASDAQ:LXEO) last released its earnings results on Monday, March 24th. The company reported ($0.78) EPS for the quarter, topping analysts’ consensus estimates of ($0.87) by $0.09. On average, equities research analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.